Article Text
Abstract
INTRODUCTION
Riluzole is the only agent approved as a disease-modifying treatment for motor neurone disease (MND). It may, or may not (depending on how one views the evidence), modify the rate of disease progression. We will examine the use of this drug that is generally viewed to have at best only a limited impact on survival in a miserable disease. With the general neurologist in mind, we hope to present a balanced view of the available evidence, with thoughts for future research and what we do in our own practice. We will highlight some of the scientific and ethical issues posed by disorders like MND, and the constraints imposed by the priorities of the pharmaceutical industry and state-sponsored research bodies.
WHAT IS THE IDEAL?
What then are the desirable features of a disease-modifying therapy for MND? We propose the following:
significant increase in survival – at least 4 months (i.e.
Statistics from Altmetric.com
Other content recommended for you
- Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial)
- Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000
- Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
- The management of motor neurone disease
- Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
- Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China
- Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
- A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland
- Amyotrophic lateral sclerosis and motor neuron syndromes in Asia
- Genetic factors affecting survival in Japanese patients with sporadic amyotrophic lateral sclerosis: a genome-wide association study and verification in iPSC-derived motor neurons from patients